Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOGEN INC.BIIB · Entity 1675 | VP, Chief Accounting Officer | March 01, 2018 | March 05, 2018 |
| NOVAVAX INCNVAX · Entity 4632 | EVP, Chief Financial Officer | November 16, 2020 | November 18, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOGEN INC.
Report date March 01, 2018 · Filed March 05, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2021-03-01 | Direct | 531 |
Reported balance
After 2018-03-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-03-01 · Grant · Acquired 531 · Balance 531 F1: The restricted stock units vest in three (3) equal annual installments commencing one year after the grant date of 03/01/2018. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units vest in three (3) equal annual installments commencing one year after the grant date of 03/01/2018.
NOVAVAX INC
Report date November 16, 2020 · Filed November 18, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 7,300 |
Reported balance
After 2020-11-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-11-16 · Grant · Acquired 7,300 · Balance 7,300 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. F2: One-third (1/3) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan"), will vest on each of the first three (3) anniversaries of the November 16, 2020 grant date (the "Grant Date"), subject to continued employment through each such vesting date. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $90.65 · Expires 2030-11-16 | Direct | 8,200 |
Reported balance
After 2020-11-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-11-16 · Grant · Acquired 8,200 · Balance 8,200 F3: Twenty-five percent (25%) of the shares subject to this option grant under the Plan will vest on the first anniversary of the Grant Date, and the remaining seventy-five percent (75%) of the shares will vest in equal monthly installments over the following three (3) years, in each case subject to continued employment through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock.
F2: One-third (1/3) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan"), will vest on each of the first three (3) anniversaries of the November 16, 2020 grant date (the "Grant Date"), subject to continued employment through each such vesting date.
F3: Twenty-five percent (25%) of the shares subject to this option grant under the Plan will vest on the first anniversary of the Grant Date, and the remaining seventy-five percent (75%) of the shares will vest in equal monthly installments over the following three (3) years, in each case subject to continued employment through such vesting date.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Renovacor, Inc.
Report date December 01, 2022 · Filed December 05, 2022
Section 16 reporting ended · disclosed 2022-12-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Expires 2031-09-03 | Direct | 0 |
Reported balance
After 2022-12-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-12-01 · Disposition to issuer · Disposed 24,000 · Balance 0 F1: Represents Company Options (as defined in the Agreement and Plan of Merger, dated as of September 19, 2022, by and among the Issuer, Rocket Pharmaceuticals, Inc. ("Rocket") and the other parties thereto (the "Merger Agreement")), whether vested or unvested, that were assumed by Rocket in the merger and replaced with an option to purchase a number of Rocket common stock equal to the product of (A) the number of Issuer shares subject to such Company Option as of immediately prior to the First Effective Time (as defined in the Merger Agreement), multiplied by (B) the Exchange Ratio (as defined in the Merger Agreement), rounded down to the nearest whole number of Rocket common stock, at an exercise price per Rocket common stock underlying such option equal to the quotient obtained by dividing (x) the per share exercise price of Company Options immediately prior to the First Effective Time by (y) the Exchange Ratio, rounded up to the nearest whole cent. F2: Each Company Option described herein shall be subject to the same terms and conditions as applied to the corresponding Company Option as of immediately prior to the First Effective Time, except as otherwise provided in the Merger Agreement. |
| Stock OptionSEC Table II · derivative / convertible security · Expires 2032-05-25 | Direct | 0 |
Reported balance
After 2022-12-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-12-01 · Disposition to issuer · Disposed 12,000 · Balance 0 F1: Represents Company Options (as defined in the Agreement and Plan of Merger, dated as of September 19, 2022, by and among the Issuer, Rocket Pharmaceuticals, Inc. ("Rocket") and the other parties thereto (the "Merger Agreement")), whether vested or unvested, that were assumed by Rocket in the merger and replaced with an option to purchase a number of Rocket common stock equal to the product of (A) the number of Issuer shares subject to such Company Option as of immediately prior to the First Effective Time (as defined in the Merger Agreement), multiplied by (B) the Exchange Ratio (as defined in the Merger Agreement), rounded down to the nearest whole number of Rocket common stock, at an exercise price per Rocket common stock underlying such option equal to the quotient obtained by dividing (x) the per share exercise price of Company Options immediately prior to the First Effective Time by (y) the Exchange Ratio, rounded up to the nearest whole cent. F2: Each Company Option described herein shall be subject to the same terms and conditions as applied to the corresponding Company Option as of immediately prior to the First Effective Time, except as otherwise provided in the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents Company Options (as defined in the Agreement and Plan of Merger, dated as of September 19, 2022, by and among the Issuer, Rocket Pharmaceuticals, Inc. ("Rocket") and the other parties thereto (the "Merger Agreement")), whether vested or unvested, that were assumed by Rocket in the merger and replaced with an option to purchase a number of Rocket common stock equal to the product of (A) the number of Issuer shares subject to such Company Option as of immediately prior to the First Effective Time (as defined in the Merger Agreement), multiplied by (B) the Exchange Ratio (as defined in the Merger Agreement), rounded down to the nearest whole number of Rocket common stock, at an exercise price per Rocket common stock underlying such option equal to the quotient obtained by dividing (x) the per share exercise price of Company Options immediately prior to the First Effective Time by (y) the Exchange Ratio, rounded up to the nearest whole cent.
F2: Each Company Option described herein shall be subject to the same terms and conditions as applied to the corresponding Company Option as of immediately prior to the First Effective Time, except as otherwise provided in the Merger Agreement.
TESARO, Inc.
Report date January 22, 2019 · Filed January 22, 2019
Section 16 reporting ended · disclosed 2019-01-22. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2019-01-22 transaction · row 1
1 source rowRow 1 · 2019-01-22 · Other · Disposed 2,156 · Balance 0 F1: Tendered in connection with the tender offer made by Adriatic Acquisition Corporation, a Delaware corporation ("Purchaser") and a wholly-owned subsidiary of GlaxoSmithKline plc, a public company organized under the laws of England and Wales ("Parent"), to purchase all of the issued and outstanding shares of TESARO, Inc., a Delaware corporation ("TESARO"), for $75.00 per share, pursuant to the terms of that certain Agreement and Plan of Merger, dated as of December 3, 2018 by and among TESARO, Purchaser, and Parent (the "Merger Agreement"). |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2019-01-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-01-22 · Disposition to issuer · Disposed 1,525 · Balance 0 F2: Each restricted stock unit represents a contingent right to receive one share of TESARO common stock. F3: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2019-01-22 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-01-22 · Disposition to issuer · Disposed 17,174 · Balance 0 F2: Each restricted stock unit represents a contingent right to receive one share of TESARO common stock. F3: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $40.55 · Expires 2028-07-16 | Direct | 0 |
Reported balance
After 2019-01-22 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-01-22 · Disposition to issuer · Disposed 29,509 · Balance 0 F4: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. |
Filing footnotes · ownership attribution and instrument terms
F1: Tendered in connection with the tender offer made by Adriatic Acquisition Corporation, a Delaware corporation ("Purchaser") and a wholly-owned subsidiary of GlaxoSmithKline plc, a public company organized under the laws of England and Wales ("Parent"), to purchase all of the issued and outstanding shares of TESARO, Inc., a Delaware corporation ("TESARO"), for $75.00 per share, pursuant to the terms of that certain Agreement and Plan of Merger, dated as of December 3, 2018 by and among TESARO, Purchaser, and Parent (the "Merger Agreement").
F2: Each restricted stock unit represents a contingent right to receive one share of TESARO common stock.
F3: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share.
F4: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd]
F5: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 01, 2022 Filed Dec 5, 2022 21:23 UTC | Renovacor, Inc. RCOR · Entity 114644 | Disposition to issuerStock Option · Derivative | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-023385 · form4.xml · derivative · entry 2 COVINO GREGORY F · CIK 0001224116 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2032-05-25 F1 · derivative.exercise_price: Represents Company Options (as defined in the Agreement and Plan of Merger, dated as of September 19, 2022, by and among the Issuer, Rocket Pharmaceuticals, Inc. ("Rocket") and the other parties thereto (the "Merger Agreement")), whether vested or unvested, that were assumed by Rocket in the merger and replaced with an option to purchase a number of Rocket common stock equal to the product of (A) the number of Issuer shares subject to such Company Option as of immediately prior to the First Effective Time (as defined in the Merger Agreement), multiplied by (B) the Exchange Ratio (as defined in the Merger Agreement), rounded down to the nearest whole number of Rocket common stock, at an exercise price per Rocket common stock underlying such option equal to the quotient obtained by dividing (x) the per share exercise price of Company Options immediately prior to the First Effective Time by (y) the Exchange Ratio, rounded up to the nearest whole cent. F2 · derivative.exercise_date: Each Company Option described herein shall be subject to the same terms and conditions as applied to the corresponding Company Option as of immediately prior to the First Effective Time, except as otherwise provided in the Merger Agreement. Read SEC document |
| December 01, 2022 Filed Dec 5, 2022 21:23 UTC | Renovacor, Inc. RCOR · Entity 114644 | Disposition to issuerStock Option · Derivative | 24,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-023385 · form4.xml · derivative · entry 1 COVINO GREGORY F · CIK 0001224116 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,000 shares Expires 2031-09-03 F1 · derivative.exercise_price: Represents Company Options (as defined in the Agreement and Plan of Merger, dated as of September 19, 2022, by and among the Issuer, Rocket Pharmaceuticals, Inc. ("Rocket") and the other parties thereto (the "Merger Agreement")), whether vested or unvested, that were assumed by Rocket in the merger and replaced with an option to purchase a number of Rocket common stock equal to the product of (A) the number of Issuer shares subject to such Company Option as of immediately prior to the First Effective Time (as defined in the Merger Agreement), multiplied by (B) the Exchange Ratio (as defined in the Merger Agreement), rounded down to the nearest whole number of Rocket common stock, at an exercise price per Rocket common stock underlying such option equal to the quotient obtained by dividing (x) the per share exercise price of Company Options immediately prior to the First Effective Time by (y) the Exchange Ratio, rounded up to the nearest whole cent. F2 · derivative.exercise_date: Each Company Option described herein shall be subject to the same terms and conditions as applied to the corresponding Company Option as of immediately prior to the First Effective Time, except as otherwise provided in the Merger Agreement. Read SEC document |
| May 25, 2022 Filed May 27, 2022 16:05 UTC | Renovacor, Inc. RCOR · Entity 114644 | GrantStock Option · Derivative | 12,000 | $0.00 Strike: $1.94 | $0.00 |
DisclosureSEC source: 0001062993-22-013697 · form4.xml · derivative · entry 1 COVINO GREGORY F · CIK 0001224116 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2032-05-25 F1 · derivative.exercise_date: The option vests on the earlier of (a) May 25, 2023, or (b) the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| September 03, 2021 Filed Sep 8, 2021 19:03 UTC | Renovacor, Inc. RCOR · Entity 114644 | GrantOption · Derivative | 24,000 | $0.00 Strike: $7.73 | $0.00 |
DisclosureSEC source: 0001192482-21-000715 · edgar.xml · derivative · entry 1 COVINO GREGORY F · CIK 0001224116 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2031-09-03 F1 · derivative.exercise_date: The stock options will vest and become exercisable 25% on the first anniversary of the grant and the remainder will vest and become exercisable in 36 equal monthly installments on the 3rd of each month for the remaining 36 months, subject to the Reporting Person's continuous service as of each such date. Read SEC document |
| November 16, 2020 Filed Nov 18, 2020 23:06 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantStock Option (Right to buy) · Derivative | 8,200 | $0.00 Strike: $90.65 | $0.00 |
DisclosureSEC source: 0001209191-20-059194 · doc4.xml · derivative · entry 2 COVINO GREGORY F · CIK 0001224116 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,200 Underlying: Common Stock · 8,200 shares Expires 2030-11-16 F3 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to this option grant under the Plan will vest on the first anniversary of the Grant Date, and the remaining seventy-five percent (75%) of the shares will vest in equal monthly installments over the following three (3) years, in each case subject to continued employment through such vesting date. Read SEC document |
| November 16, 2020 Filed Nov 18, 2020 23:06 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantRestricted Stock Units · Derivative | 7,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-059194 · doc4.xml · derivative · entry 1 COVINO GREGORY F · CIK 0001224116 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,300 Underlying: Common Stock · 7,300 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. F2 · derivative.exercise_date: One-third (1/3) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan"), will vest on each of the first three (3) anniversaries of the November 16, 2020 grant date (the "Grant Date"), subject to continued employment through each such vesting date. F2 · derivative.expiration_date: One-third (1/3) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan"), will vest on each of the first three (3) anniversaries of the November 16, 2020 grant date (the "Grant Date"), subject to continued employment through each such vesting date. Read SEC document |
| January 22, 2019 Filed Jan 22, 2019 09:56 UTC | TESARO, Inc. TSRO · Entity 160894 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 29,509 | Not disclosed Strike: $40.55 | Not disclosed |
DisclosureSEC source: 0001123292-19-000165 · edgar.xml · derivative · entry 4 COVINO GREGORY F · CIK 0001224116 · SVP, CAO, PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 29,509 shares Expires 2028-07-16 F4 · price: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5 · price: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5 · derivative.exercise_date: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. Read SEC document |
| January 22, 2019 Filed Jan 22, 2019 09:56 UTC | TESARO, Inc. TSRO · Entity 160894 | Disposition to issuerRestricted Stock Units · Derivative | 17,174 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001123292-19-000165 · edgar.xml · derivative · entry 3 COVINO GREGORY F · CIK 0001224116 · SVP, CAO, PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,174 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of TESARO common stock. F3 · price: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share. F3 · derivative.exercise_date: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share. F3 · derivative.expiration_date: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share. Read SEC document |
| January 22, 2019 Filed Jan 22, 2019 09:56 UTC | TESARO, Inc. TSRO · Entity 160894 | Disposition to issuerRestricted Stock Units · Derivative | 1,525 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001123292-19-000165 · edgar.xml · derivative · entry 2 COVINO GREGORY F · CIK 0001224116 · SVP, CAO, PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,525 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of TESARO common stock. F3 · price: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share. F3 · derivative.exercise_date: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share. F3 · derivative.expiration_date: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share. Read SEC document |
| January 22, 2019 Filed Jan 22, 2019 09:56 UTC | TESARO, Inc. TSRO · Entity 160894 | OtherCommon Stock | 2,156 | $75.00 | $161,700.00 |
DisclosureSEC source: 0001123292-19-000165 · edgar.xml · nonDerivative · entry 1 COVINO GREGORY F · CIK 0001224116 · SVP, CAO, PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Tendered in connection with the tender offer made by Adriatic Acquisition Corporation, a Delaware corporation ("Purchaser") and a wholly-owned subsidiary of GlaxoSmithKline plc, a public company organized under the laws of England and Wales ("Parent"), to purchase all of the issued and outstanding shares of TESARO, Inc., a Delaware corporation ("TESARO"), for $75.00 per share, pursuant to the terms of that certain Agreement and Plan of Merger, dated as of December 3, 2018 by and among TESARO, Purchaser, and Parent (the "Merger Agreement"). Read SEC document |
| December 20, 2018 Filed Dec 21, 2018 19:18 UTC | TESARO, Inc. TSRO · Entity 160894 | Exercise / conversionRestricted Stock Units · Derivative | 3,055 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-074521 · a4.xml · derivative · entry 3 COVINO GREGORY F · CIK 0001224116 · SVP,CAO,PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,525 Underlying: Common Stock · 3,055 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represented a contingent right to receive one share of TESARO common stock. F2 · derivative.exercise_date: On December 20, 2018, the Compensation Committee of the Board of Directors of TESARO accelerated the vesting of a portion of the restricted stock units, which were previously scheduled to vest on July 16, 2020. The remaining restricted stock units will vest on July 16, 2020 in accordance with the original vesting schedule. F2 · derivative.expiration_date: On December 20, 2018, the Compensation Committee of the Board of Directors of TESARO accelerated the vesting of a portion of the restricted stock units, which were previously scheduled to vest on July 16, 2020. The remaining restricted stock units will vest on July 16, 2020 in accordance with the original vesting schedule. Read SEC document |
| December 20, 2018 Filed Dec 21, 2018 19:18 UTC | TESARO, Inc. TSRO · Entity 160894 | Tax withholdingCommon Stock | 899 | $73.10 | $65,716.90 |
DisclosureSEC source: 0001104659-18-074521 · a4.xml · nonDerivative · entry 2 COVINO GREGORY F · CIK 0001224116 · SVP,CAO,PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,156 Read SEC document |
| December 20, 2018 Filed Dec 21, 2018 19:18 UTC | TESARO, Inc. TSRO · Entity 160894 | Exercise / conversionCommon Stock | 3,055 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-074521 · a4.xml · nonDerivative · entry 1 COVINO GREGORY F · CIK 0001224116 · SVP,CAO,PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,055 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 21:35 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 531 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-010078 · form4.xml · derivative · entry 1 COVINO GREGORY F · CIK 0001224116 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 531 Underlying: Common Stock · 531 shares Expires 2021-03-01 F1 · derivative.exercise_date: The restricted stock units vest in three (3) equal annual installments commencing one year after the grant date of 03/01/2018. Read SEC document |
| February 23, 2018 Filed Feb 27, 2018 23:24 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 116 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-008813 · form4.xml · derivative · entry 4 COVINO GREGORY F · CIK 0001224116 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 116 shares Expires 2018-02-23 F2 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 23, 2018 Filed Feb 27, 2018 23:24 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 92 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-008813 · form4.xml · derivative · entry 3 COVINO GREGORY F · CIK 0001224116 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116 Underlying: Common Stock · 92 shares Expires 2018-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 23, 2018 Filed Feb 27, 2018 23:24 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 28 | $292.78 | $8,197.84 |
DisclosureSEC source: 0001127602-18-008813 · form4.xml · nonDerivative · entry 2 COVINO GREGORY F · CIK 0001224116 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,744.3601 Read SEC document |
| February 23, 2018 Filed Feb 27, 2018 23:24 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 92 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-008813 · form4.xml · nonDerivative · entry 1 COVINO GREGORY F · CIK 0001224116 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,772.3601 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2018 Filed Feb 26, 2018 21:11 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 100 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-008404 · form4.xml · derivative · entry 4 COVINO GREGORY F · CIK 0001224116 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 302 Underlying: Common Stock · 100 shares Expires 2019-02-22 F2 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 22, 2018 Filed Feb 26, 2018 21:11 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 194 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-008404 · form4.xml · derivative · entry 3 COVINO GREGORY F · CIK 0001224116 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 402 Underlying: Common Stock · 194 shares Expires 2019-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 22, 2018 Filed Feb 26, 2018 21:11 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 58 | $284.81 | $16,518.98 |
DisclosureSEC source: 0001127602-18-008404 · form4.xml · nonDerivative · entry 2 COVINO GREGORY F · CIK 0001224116 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,680.3601 Read SEC document |
| February 22, 2018 Filed Feb 26, 2018 21:11 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 194 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-008404 · form4.xml · nonDerivative · entry 1 COVINO GREGORY F · CIK 0001224116 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,738.3601 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 21:18 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 95 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-007189 · form4.xml · derivative · entry 4 COVINO GREGORY F · CIK 0001224116 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 514 Underlying: Common Stock · 95 shares Expires 2020-02-15 F2 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 21:18 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 161 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-007189 · form4.xml · derivative · entry 3 COVINO GREGORY F · CIK 0001224116 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 609 Underlying: Common Stock · 161 shares Expires 2020-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 21:18 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 56 | $299.38 | $16,765.28 |
DisclosureSEC source: 0001127602-18-007189 · form4.xml · nonDerivative · entry 2 COVINO GREGORY F · CIK 0001224116 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,544.3601 Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 21:18 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 161 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-007189 · form4.xml · nonDerivative · entry 1 COVINO GREGORY F · CIK 0001224116 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,600.3601 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 23:42 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 1,390 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-006187 · form4.xml · derivative · entry 2 COVINO GREGORY F · CIK 0001224116 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,390 Underlying: Common Stock · 1,390 shares Expires 2021-02-12 F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 23:42 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 345 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-006187 · form4.xml · derivative · entry 1 COVINO GREGORY F · CIK 0001224116 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 345 Underlying: Common Stock · 345 shares Expires 2020-02-12 F1 · derivative.exercise_date: The restricted stock units will vest in 2 annual installments. One-third will vest on the first anniversary of the grant date and two-thirds will vest on the second anniversary of the grant date. Read SEC document |
| December 01, 2017 Filed Dec 5, 2017 21:36 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 103 | $319.35 | $32,893.05 |
DisclosureSEC source: 0001127602-17-033936 · form4.xml · nonDerivative · entry 2 COVINO GREGORY F · CIK 0001224116 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,439.3601 Read SEC document |
| December 01, 2017 Filed Dec 5, 2017 21:36 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 54 | $319.35 | $17,244.90 |
DisclosureSEC source: 0001127602-17-033936 · form4.xml · nonDerivative · entry 1 COVINO GREGORY F · CIK 0001224116 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,542.3601 F1 · balance_after: Includes 86.155 shares and 5.382 shares acquired under the Biogen Inc. employee stock purchase plan on 3/31/2017 and 6/30/2017, respectively. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:18 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 121 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009812 · form4.xml · derivative · entry 15 COVINO GREGORY F · CIK 0001224116 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 121 shares Expires 2017-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · date: This award vested on 2/12/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. F11 · shares: This award was previously reported as covering 258 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017 F5 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). F11 · derivative.underlying_shares: This award was previously reported as covering 258 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017 F11 · balance_after: This award was previously reported as covering 258 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017 Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:18 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 321 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009812 · form4.xml · derivative · entry 14 COVINO GREGORY F · CIK 0001224116 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 321 shares Expires 2017-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · date: This award vested on 2/12/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. F9 · shares: This award was previously reported as covering 315 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017 F10 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 150% of the number of shares at target payout. One-fourth of these RSUs are eligible to vest on each of the first four anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen Idec common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the average 60 calendar-day closing stock price ending on the vesting date divided by the average 60 calendar-day closing stock price on the grant date]). F9 · derivative.underlying_shares: This award was previously reported as covering 315 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017 F9 · balance_after: This award was previously reported as covering 315 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017 Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:18 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 163 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009812 · form4.xml · derivative · entry 13 COVINO GREGORY F · CIK 0001224116 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 596 Underlying: Common Stock · 163 shares Expires 2019-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · date: This award vested on 2/22/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. F8 · shares: This award was previously reported as covering 870 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017 F6 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). F8 · derivative.underlying_shares: This award was previously reported as covering 870 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017 F8 · balance_after: This award was previously reported as covering 870 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017 Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:18 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 76 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009812 · form4.xml · derivative · entry 12 COVINO GREGORY F · CIK 0001224116 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208 Underlying: Common Stock · 76 shares Expires 2018-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: This award vested on 2/23/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. F7 · shares: This award was previously reported as covering 402 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017 F5 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). F7 · derivative.underlying_shares: This award was previously reported as covering 402 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017 F7 · balance_after: This award was previously reported as covering 402 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017 Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:18 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 128 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009812 · form4.xml · derivative · entry 11 COVINO GREGORY F · CIK 0001224116 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 284 Underlying: Common Stock · 128 shares Expires 2018-02-23 F4 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F5 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:18 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 131 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009812 · form4.xml · derivative · entry 10 COVINO GREGORY F · CIK 0001224116 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 759 Underlying: Common Stock · 131 shares Expires 2019-02-22 F4 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F6 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:18 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 143 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009812 · form4.xml · derivative · entry 9 COVINO GREGORY F · CIK 0001224116 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121 Underlying: Common Stock · 143 shares Expires 2017-02-12 F4 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F5 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:18 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 3 | $274.76 | $824.28 |
DisclosureSEC source: 0001127602-17-009812 · form4.xml · nonDerivative · entry 8 COVINO GREGORY F · CIK 0001224116 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,504.8231 F3 · date: This award vested on 2/12/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:18 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 121 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009812 · form4.xml · nonDerivative · entry 7 COVINO GREGORY F · CIK 0001224116 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,507.8231 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · date: This award vested on 2/12/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:18 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 8 | $274.76 | $2,198.08 |
DisclosureSEC source: 0001127602-17-009812 · form4.xml · nonDerivative · entry 6 COVINO GREGORY F · CIK 0001224116 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,386.8231 F3 · date: This award vested on 2/12/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:18 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 321 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009812 · form4.xml · nonDerivative · entry 5 COVINO GREGORY F · CIK 0001224116 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,394.8231 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · date: This award vested on 2/12/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:18 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 53 | $287.63 | $15,244.39 |
DisclosureSEC source: 0001127602-17-009812 · form4.xml · nonDerivative · entry 4 COVINO GREGORY F · CIK 0001224116 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,073.8231 F2 · date: This award vested on 2/22/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:18 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 163 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009812 · form4.xml · nonDerivative · entry 3 COVINO GREGORY F · CIK 0001224116 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,126.8231 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · date: This award vested on 2/22/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:18 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 25 | $284.75 | $7,118.75 |
DisclosureSEC source: 0001127602-17-009812 · form4.xml · nonDerivative · entry 2 COVINO GREGORY F · CIK 0001224116 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,963.8231 F1 · date: This award vested on 2/23/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:18 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 76 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009812 · form4.xml · nonDerivative · entry 1 COVINO GREGORY F · CIK 0001224116 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,988.8231 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: This award vested on 2/23/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. Read SEC document |
| February 15, 2017 Filed Feb 18, 2017 01:24 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 770 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-007113 · form4.xml · derivative · entry 1 COVINO GREGORY F · CIK 0001224116 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 770 Underlying: Common Stock · 770 shares Expires 2020-02-15 F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| December 01, 2016 Filed Dec 5, 2016 21:32 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 53 | $295.78 | $15,676.34 |
DisclosureSEC source: 0001127602-16-069149 · form4.xml · nonDerivative · entry 2 COVINO GREGORY F · CIK 0001224116 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,883.8231 Read SEC document |
| December 01, 2016 Filed Dec 5, 2016 21:32 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantCommon Stock | 930 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-16-069149 · form4.xml · nonDerivative · entry 1 COVINO GREGORY F · CIK 0001224116 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,936.8231 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.